Happy to s_老虎社区_美港股上老虎

Investcub
2021-11-22

Happy to see competition is heating up!!!

Novartis plans new sales approach for cholesterol lowering drug - WSJ

In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sale

Novartis plans new sales approach for cholesterol lowering drug - WSJ

免责声明：上述内容仅代表发帖人个人观点，不构成本平台的任何投资建议。

推荐
最新

暂无评论

热议股票

关于我们·老虎社区守则·老虎社区账号管理规范·老虎社区服务协议·老虎社区隐私政策

公司名称：北京至简风宜信息技术有限公司

违法和不良信息投诉：010-5681-3562（工作时间9:30-18:30）

邮箱：service@laohu8.com

营业执照：91110105MA01A4U55R

ICP备：京ICP备18016422号

网安备：京公网安备11010502036490

关注我们

{"i18n":{"language":"zh_CN"},"data":{"magic":2,"id":875060514,"tweetId":"875060514","gmtCreate":1637588833510,"gmtModify":1637588855672,"author":{"id":3584582153384625,"authorId":3584582153384625,"authorIdStr":"3584582153384625","name":"Investcub","avatar":"https://static.tigerbbs.com/b34bc19b19d991e55d86b53b1e4a44ff","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":5,"crmLevelSwitch":0,"individualDisplayBadges":[],"fanSize":39,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"extraTitle":"","html":"<html><head></head><body><p>Happy to see competition is heating up!!!</p></body></html>","htmlText":"<html><head></head><body><p>Happy to see competition is heating up!!!</p></body></html>","text":"Happy to see competition is heating up!!!","highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://laohu8.com/post/875060514","repostId":1135443897,"repostType":4,"repost":{"id":"1135443897","pubTimestamp":1637584143,"share":"https://www.laohu8.com/m/news/1135443897?lang=&edition=full","pubTime":"2021-11-22 20:29","market":"us","language":"en","title":"Novartis plans new sales approach for cholesterol lowering drug - WSJ","url":"https://stock-news.laohu8.com/highlight/detail?id=1135443897","media":"seekingalpha","summary":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sale","content":"<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio,&nbsp;<i>TheWall Street&nbsp;Journal</i>&nbsp;reports.</p>\n<p>Unlike a promotional strategy reliant on sales representatives, the Swiss pharma giant plans to sell Leqvio targeting 200 hospital systems across the nation.</p>\n<p>Through the so-called population health approach, the company expects the health care systems through electronic health records to assist it in identifying the patients who could qualify for the drug after failing to control their cholesterol with current therapies.</p>\n<p>For decades, patients took statins to control the type of cholesterol, low-density lipoprotein, or LDL targeted by Leqvio.</p>\n<p>However, the twice-yearly injection is said to be more powerful than statins and competes against Repatha from Amgen(NASDAQ:AMGN)and Praluent from Sanofi(NASDAQ:SNY)and Regeneron(NASDAQ:REGN), two other drugs with a similar mechanism of action to Leqvio.</p>\n<p>With Repatha and Praluent requiring self-injection every two or four weeks, Novartis (NVS) expects Leqvio will have the edge with twice-yearly dosing.</p>\n<p>In late 2020, Leqvio, also called inclisiran,&nbsp;was approved in Europe.</p>","source":"seekingalpha","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Novartis plans new sales approach for cholesterol lowering drug - WSJ</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNovartis plans new sales approach for cholesterol lowering drug - WSJ\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-11-22 20:29 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj><strong>seekingalpha</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal ...</p>\n\n<a href=\"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"NVS":"诺华"},"source_url":"https://seekingalpha.com/news/3773170-novartis-plans-new-sales-approach-for-cholesterol-lowering-drug-wsj","is_english":true,"share_image_url":"https://static.laohu8.com/5a36db9d73b4222bc376d24ccc48c8a4","article_id":"1135443897","content_text":"In a bid to take on well-established rivals, Novartis(NYSE:NVS)is formulating a non-traditional sales strategy to promote the company’s cholesterol-busting therapy Leqvio, TheWall Street Journal reports.\nUnlike a promotional strategy reliant on sales representatives, the Swiss pharma giant plans to sell Leqvio targeting 200 hospital systems across the nation.\nThrough the so-called population health approach, the company expects the health care systems through electronic health records to assist it in identifying the patients who could qualify for the drug after failing to control their cholesterol with current therapies.\nFor decades, patients took statins to control the type of cholesterol, low-density lipoprotein, or LDL targeted by Leqvio.\nHowever, the twice-yearly injection is said to be more powerful than statins and competes against Repatha from Amgen(NASDAQ:AMGN)and Praluent from Sanofi(NASDAQ:SNY)and Regeneron(NASDAQ:REGN), two other drugs with a similar mechanism of action to Leqvio.\nWith Repatha and Praluent requiring self-injection every two or four weeks, Novartis (NVS) expects Leqvio will have the edge with twice-yearly dosing.\nIn late 2020, Leqvio, also called inclisiran, was approved in Europe.","news_type":1},"isVote":1,"tweetType":1,"viewCount":378,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"CN","currentLanguage":"CN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"upFlag":false,"length":35,"xxTargetLangEnum":"ZH_CN"},"commentList":[],"hasMoreComment":false,"orderType":2}